Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554145 | 0.82 | SLC40A1 (0.51) | SLC40A1PPIASMN1; SMN2BRD4RPS6KB1 | |
| SCHEMBL18347805 | 0.78 | SLC40A1 (0.43) | SLC40A1PPIABRD4SGMS2 | |
| SCHEMBL16878631 | 0.77 | MAPT (0.45) | PPIASMN1; SMN2PKM | |
| SCHEMBL8110769 | 0.76 | KMT2A (0.49) | SLC40A1SMN1; SMN2HDAC6 | |
| SCHEMBL16887761 | 0.76 | HTT (0.61) | TOP2ASMN1; SMN2PDE4D | |
| SCHEMBL3307110 | 0.76 | MAPT (0.56) | SLC40A1PPIASMN1; SMN2SGMS2PDE4D | |
| SCHEMBL23360351 | 0.74 | PRMT5 (0.51) | BRD4 | |
| SCHEMBL8025399 | 0.74 | TOP2A (0.51) | TOP2ASMN1; SMN2PDE4D | |
| SCHEMBL16407670 | 0.73 | PSMD14 (0.53) | SLC40A1SMN1; SMN2 | |
| SCHEMBL29259247 | 0.73 | MAPT (0.47) | SLC40A1SMN1; SMN2PDE4DHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766882-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | YUNGJIN PHARM CO., LTD. (KR) | 2020-09-08 | — | — | US | disclosed |
| US-9975883-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | YUNGJIN PHARM. CO., LTD. (KR) | 2018-05-22 | — | — | US | disclosed |
| US-9975883-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | YUNGJIN PHARM. CO., LTD. (KR) | 2018-05-22 | — | — | US | disclosed |
| US-20160376258-A1 | 1,2-NAPHTHOQUINONE BASED DERIVATIVE AND METHOD OF PREPARING THE SAME | KT&G LIFE SCIENCES CORPORATION (KR) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766882-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | CYP2S1, GYS2, SLC5A1 | SLC40A1 1868/4885TOP2A 846/4885PPIA 3413/4885 |
| US-20160376258-A1 | 1,2-NAPHTHOQUINONE BASED DERIVATIVE AND METHOD OF PREPARING THE SAME | CYP2S1, GYS2, SLC5A1 | SLC40A1 1868/4885TOP2A 846/4885PPIA 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.